Hugel (145020) Q4 2024 earnings summary

Executive summary

• Net sales for 4Q24 reached KRW 98.2bn, up 10.4% year-over-year, with full-year sales at KRW 373.0bn, a 16.7% increase.

• Net income for 4Q24 was KRW 40.7bn, up 130.0% year-over-year; full-year net income was KRW 142.4bn, up 45.8%.

Financial highlights

• Gross profit for 4Q24 was KRW 75.8bn, up 13.1% year-over-year, with a gross margin of 77.2%.

• Operating profit for 4Q24 was KRW 46.6bn, up 26.7% year-over-year; operating margin improved to 47.4%.

• SG&A expenses decreased 3.4% year-over-year in 4Q24.

• Pre-tax income for 4Q24 was KRW 35.3bn, up 44.4% year-over-year.

Segment performance

• Toxin product sales in 4Q24 were KRW 53.2bn, up 9.0% year-over-year; full-year sales rose 20.2%.

• Filler sales in 4Q24 were KRW 31.9bn, up 6.4% year-over-year; full-year sales increased 8.3%.

• Cosmetics sales in 4Q24 were KRW 11.7bn, up 48.1% year-over-year; full-year sales up 37.8%.

• Thread and Others segment declined 40.8% year-over-year in 4Q24.

• International sales for Toxin & Filler in 4Q24 were KRW 56.6bn, up 10.7% year-over-year; Asia Pacific region grew 14.2%.